-
Mashup Score: 9
Published online: May 01, 2024 Request permissions for this article. Health Sciences North Research Institute, Northern Ontario School of Medicine, Health Sciences North, Sudbury, Ontario, Canada Cleveland Clinic, Cleveland, OH American Society of Clinical Oncology, Alexandria, VA University of Washington School of Medicine, Seattle, WA UPMC Hillman Cancer Center, Pittsburgh, PA University of Pittsburgh, Pittsburgh, PA Department of Dental Oncology, Princess Margaret Cancer Center/Faculty of Dentistry,
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
PURPOSE Real-world evidence comparing health care resource use (HRU) and costs between novel targeted therapies among patients with chronic lymphocytic leukemia (CLL) is lacking. We compared all-cause and CLL-specific HRU and costs between patients initiated on B-cell lymphoma 2 inhibitor (venetoclax)– or Bruton tyrosine kinase inhibitor (BTKi)–based regimens in the second-line (2L) setting. METHODS This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January 2018-December 2021) for the first time and had ≥one CLL diagnostic claim after 2L initiation and ≥two claims for venetoclax or BTKi. Baseline characteristics were balanced using stabilized inverse probability of treatment weights. Mean monthly cost difference (MMCD) between cohorts for all-cause and CLL-specific per patient per month (PPPM) costs was estimated. Rates of PPPM-HRU were compared between
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma - 5 day(s) ago
PURPOSE Guidelines recommend germline genetic testing (GT) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aims to evaluate the utilization and outcomes of multigene panel GT in patients with PDAC. METHODS This retrospective, multisite study included patients with PDAC diagnosed between May 2018 and August 2020 at Mayo Clinic Arizona, Florida, and Minnesota. Discussion, uptake, and outcomes of GT were compared before (May 1, 2018-May 1, 2019) and after (August 1, 2019-August 1, 2020) the guideline update, accounting for a transition period. RESULTS The study identified 533 patients with PDAC, with 321 (60.2%) preguideline and 212 (39.8%) postguideline. Patient characteristics did not differ between the preguideline and postguideline periods. GT was discussed in 34.3% (110 of 321) of preguideline and 39.6% (84 of 212) of postguideline patients (odds ratio [OR], 1.26 [95% CI, 0.88 to 1.80]) and subsequently performed in 80.9% (89 of 110) of preguideline and 75.0% (6
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
PURPOSE Several allelic variants of the gene DPYD encoding dihydropyrimidine dehydrogenase (DPD) are associated with impaired metabolism of the systemic fluoropyrimidine fluorouracil (5FU) and its oral prodrug, capecitabine, which elevates the risk for severe toxicity. Following a patient death related to capecitabine toxicity in which DPD deficiency was suspected, a multidisciplinary advisory panel was convened to develop an institution-wide approach to future patients planned for a systemic fluoropyrimidine. METHODS The panel selected an opt-out testing strategy which focused on developing reliable processes to collect and report test results and targeted education. An electronic health record–based automated reminder was designed to activate when a 5FU- or capecitabine-containing chemotherapy regimen was ordered for a patient without prior exposure to either agent and without a prior DPYD sequencing test result. DPYD testing was standardized across all sites of care, and a closed lo
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
A multiprong set of interventions led to ⬆️ rate (baseline 26% to a sustained rate of >90%) of preemptive #DPYD testing for pts planned for a systemic fluoropyrimidine. Implementing an opt-out, reminder-based program may save lives. ➡️ https://t.co/Gty41hJl2o #impsci @Labrat3 https://t.co/td4BzenH9s
-
-
Mashup Score: 2Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights - 20 day(s) ago
Published online: April 08, 2024 Request permissions for this article. Ohio State University, Columbus, OH Corewell Health William Beaumont University Hospital, Royal Oak and Oakland University William Beaumont School of Medicine, Rochester, MI Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada American Society of Clinical Oncology (ASCO), Alexandria, VA Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Huntsman Cancer Institute, Salt Lake City, UT Universit
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Thresholds in PROMIS Scores Anchored to Subsequent Unscheduled Health Service Use Among People Diagnosed With Cancer - 21 day(s) ago
PURPOSE To establish thresholds in the Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference, physical function, fatigue, and depression scores on the basis of their association with subsequent use of the emergency department (ED) or urgent care by people diagnosed with cancer. METHODS Retrospective data from 952 people seen at Henry Ford Cancer and insured through the Health Alliance Plan were analyzed using generalized linear mixed-effects models. The log odds of ED or urgent care use during 14 or 30 days after each patient-reported outcome (PRO) assessment were related to PRO scores, while adjusting for comorbidity, sociodemographic, and tumor characteristics. RESULTS Pain interference and physical function were associated with subsequent ED or urgent care visits, but fatigue and depression were not, and the results for 14- and 30-day visits were similar. Thresholds anchored in the likelihood of these visits differed according to cancer stage. For peopl
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
PURPOSE Estimation of the independent effect of rurality on cancer mortality requires causal inference methodology and consideration of area-level socioeconomic status and rural designations. METHODS Using SEER data, we identified key incident cancers diagnosed between 2000 and 2016 at age ≥20 years (N = 3,788,273), examining a 20% random sample (n = 757,655). Standardized competing risk and survival models estimated the association between rural residence, defined by Rural-Urban Continuum Codes, and cancer-specific and all-cause mortality, controlling for age at cancer diagnosis, sex, race/ethnicity, year of diagnosis, and Area Deprivation Index (ADI). We estimated the attributable fraction (AF) of rurality and high ADI (ADI > median) to the probability of mortality. Finally, we examined county measurement issues contributing to mortality rates discordant from hypothesized rates. RESULTS The 5-year standardized failure probability for cancer mortality for rural patients was 33.9% vers
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8Now That We Don't Talk: Should Cancer Centers Bill for Patient Portal Messages in Oncology? - 29 day(s) ago
Published online: March 21, 2024 Request permissions for this article. Massachusetts General Hospital, Concord, MA Now That We Don’t Talk: Should Cancer Centers Bill for Patient Portal Messages in Oncology?. JCO Oncol Pract 0, OP.24.00176 DOI: 10.1200/OP.24.00176 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
PURPOSE Although patients with metastatic breast cancer (MBC) have been living longer with the advent of more effective treatments such as targeted therapy and immunotherapy, the disease remains incurable, and most patients will undergo therapy indefinitely. When beginning therapy, patients are typically prescribed dose often based upon the maximum tolerated dose identified in phase I clinical trials. However, patients’ perspectives about tolerability and willingness to discuss individualized dosing of drugs upon initiation of a new regimen and throughout the course of treatment have not been comprehensively evaluated. METHODS Patient advocates and medical oncologists from the Patient-Centered Dosing Initiative (PCDI) developed a survey to ascertain the prevalence and severity of MBC patients’ treatment-related side effects, the level of patient-physician communication, mitigation strategies, perception about the relative efficacy of higher versus lower doses, and willingness to discus
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Vaccination of Adults With Cancer: ASCO Guideline Clinical Insights - 1 month(s) ago
This clinical insights article is derived from recommendations in Vaccination of Adults with Cance r: ASCO Guideline. This document is based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This clinical insights article does not purport to suggest any particular course of medical treatment. Use of the guideline and this clinical insights article are
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
Now available: ISOO-MASCC-@ASCO guideline clinical insights on prevention and management of #osteoradionecrosis in patients with #headandneckcancer treated with radiation therapy: https://t.co/JfizyzEDgR #hncsm #radonc @isooworld @CancerCareMASCC